Abelacimab, formerly known as MAA868, represents a groundbreaking approach to treating thrombosis. This blood-thinning agent is a selective monoclonal immunoglobulin that blocks the integrin αIIbβ3, a essential https://www.targetmol.com/compound/abelacimab